JAT announces distribution agreement with Healthy One
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Jat Energy Limited (ASX:JAT) today announced it has entered into a distribution agreement with Healthy One Co., Ltd (H1). H1 is a subsidiary of Hong Kong listed Tian Ge Interactive Holdings Ltd (HKSE code:1980).
H1 has been growing its online and offline distribution capacity in China for eight years. The key terms of the agreement are as follows.
Products:
- NEURIO Formulated Milk Powder With Lactoferrin
- Other Neurio brand products
- Other products supplied by JAT as agreed
Territories:
H1 has non-exclusive rights to sell the products on the following platforms and channels.
(a) Cross-border platforms
- Tmall — H1 Overseas Products Speciality Store
- Taoanju Daigou Jinguan Store
- VIP (www.vip.com)
- Taobao shop distribution
(b) Offline retail outlets
- Hangzhou Tianjiong Industry Co., Ltd(c) Sales platforms
- Global Scanner
- Nicomama
- Yunjinet.com
However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.
Payment terms
The terms of the agreement state that payment must be made in full prior to product release, with an initial term of 12 months. The term can be extended upon H1 giving at least two months written notice before the end of the term.
Following the receipt of notice, both companies will commence negotiations in good faith to determine the terms and conditions of the agreement for the extended term. There are no conditions precedent in the agreement.
First order placed
Promisingly, H1 has already placed and paid for its first order under the agreement. The order consists of one pallet (960 tins) of NEURIO Formulated Milk Powder With Lactoferrin.
This news follows JAT’s announcement earlier this week, that Golden Koala Group Pty Ltd — 51% owned subsidiary of JAT — had entered into a supply agreement with AustAgri Pty Limited. Under the agreement, Golden Koala are set to supply its Golden Koala Premium Range Infant Formulas to AustAgri for sale in mainland China, Hong Kong, Macau and Taiwan, as well as via e-commerce platforms.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
